Morphologic remission status is limited compared to ΔN flow cytometry: a Children’s Oncology Group AAML0531 report
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Morphologic remission status is limited compared to ΔN flow cytometry: a Children’s Oncology Group AAML0531 report
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 20, Pages 5050-5061
Publisher
American Society of Hematology
Online
2020-10-20
DOI
10.1182/bloodadvances.2020002070
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children’s Oncology Group
- (2020) Richard Aplenc et al. HAEMATOLOGICA
- Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies
- (2019) Barbara Buldini et al. Frontiers in Pediatrics
- Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
- (2018) Gerrit J. Schuurhuis et al. BLOOD
- Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children’s Oncology Group (COG)
- (2018) Sumit Gupta et al. LEUKEMIA
- Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
- (2017) Andrew P. Voigt et al. HAEMATOLOGICA
- The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
- (2017) Hamid Bolouri et al. NATURE MEDICINE
- Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children’s Oncology Group protocol AAML0531
- (2017) Andrew P. Voigt et al. HAEMATOLOGICA
- Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study
- (2016) Anne Tierens et al. BRITISH JOURNAL OF HAEMATOLOGY
- Consistent quantitative gene product expression: #1. Automated identification of regenerating bone marrow cell populations using support vector machines
- (2016) Andrew P. Voigt et al. CYTOMETRY PART A
- Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals
- (2016) Michael R. Loken et al. CYTOMETRY PART A
- Consistent quantitative gene product expression: #3. Invariance with age
- (2016) Michael R. Loken et al. CYTOMETRY PART A
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
- (2015) Xueyan Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of flow cytometric residual disease, dysregulated neutrophils/monocytes, and hematogones in adult acute myeloid leukemia in first remission
- (2014) Sung-Chao Chu et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
- (2014) Alan S. Gamis et al. JOURNAL OF CLINICAL ONCOLOGY
- Residual disease in AML, a target that can move in more than one direction
- (2013) Michael R. Loken CYTOMETRY PART B-CLINICAL CYTOMETRY
- Tumor heterogeneity makes AML a “moving target” for detection of residual disease
- (2013) W. Zeijlemaker et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group
- (2012) M. R. Loken et al. BLOOD
- Comparative Analysis of Different Approaches to Measure Treatment Response in Acute Myeloid Leukemia
- (2012) Hiroto Inaba et al. JOURNAL OF CLINICAL ONCOLOGY
- Flow cytometric scoring system as a diagnostic and prognostic tool in myelodysplastic syndromes
- (2011) Sung-Chao Chu et al. LEUKEMIA RESEARCH
- Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
- (2010) P. A. Ho et al. BLOOD
- Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol
- (2010) V H J van der Velden et al. LEUKEMIA
- Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group
- (2009) P. A. Ho et al. BLOOD
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started